Originally aired on Tuesday, January 21, 2020 • Hosted by the Infectious Disease Community of Practice (IDCOP)
"Ultra-short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients."
(Am J Transplant. 2019 Oct 25. doi: 10.1111/ajt.15664. [Epub ahead of print]).
In this article:
[The authors] conducted an adaptive design single-center pilot trial between October 2017 and November 2018 to determine the safety and efficacy of ultra-short-term perioperative pangenotypic direct acting antiviral (DAA) prophylaxis for deceased hepatitis C virus (HCV)-nucleic acid test (NAT) positive donors to HCV negative kidney recipients (D+/R-).... At a median follow-up of 8 months posttransplant, overall patient and allograft survivals were 98%, respectively. The 4-day strategy reduced viral transmission to 7.5% (3/40; 95% confidence interval [CI]: 1.8%-20.5%) and could result in avoidance of prolonged posttransplant DAA therapy for most D+/R - transplants.
Gaurav Gupta, MD • Virginia Commonwealth University, Richmond, VA
Richard Sterling, MD • Virginia Commonwealth University, Richmond, VA
Deirdre Sawinski, MD, FAST • University of Pennsylvania Hospital, Philadelphia, PA